A cancer drugmaker is putting its trial on hold after two patients died last week

Cancer cellGECancer cells

Seattle-based biotech Juno Therapeutics’ stock is halted after the news that its lead drug led to two deaths last week.

Juno, which has been developing a treatment that uses genetically engineered cells to go after a form of adult leukemia, said Thursday that the phase 2 trial had been put on clinical hold by the FDA.

The type of treatment is known as CAR-T, or chimeric antigen receptor T cells. This kind of treatment, in Juno’s case, uses a patient’s own T-cells, a type of blood cell that’s involved our immune system response.

This story is developing…

NOW WATCH: Everyday phrases that even smart people say incorrectly

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.